☰

Lin Wang - Publications

Affiliations: 
University of Pittsburgh, Pittsburgh, PA, United States 
Tree Info Similar researchers PubMed Report error

32 high-probability publications. We are testing a new system for linking publications to authors. You can help! If you notice any inaccuracies, please sign in and mark papers as correct or incorrect matches. If you identify any major omissions or other inaccuracies in the publication list, please let us know.

Year Citation  Score
2018 Zhang L, Li Z, Liu Y, Xu S, Tandon M, Appelboom B, LaValle CR, Chiosea SI, Wang L, Sen M, Lui VWY, Grandis JR, Wang QJ. Analysis of oncogenic activities of protein kinase D1 in head and neck squamous cell carcinoma. Bmc Cancer. 18: 1107. PMID 30419840 DOI: 10.1186/S12885-018-4965-6  0.329
2018 Lu S, Concha-Benavente F, Shayan G, Srivastava RM, Gibson SP, Wang L, Gooding WE, Ferris RL. STING activation enhances cetuximab-mediated NK cell activation and DC maturation and correlates with HPVstatus in head and neck cancer. Oral Oncology. 78: 186-193. PMID 29496049 DOI: 10.1016/J.Oraloncology.2018.01.019  0.329
2017 Stabile LP, Egloff AM, Gibson MK, Gooding WE, Ohr J, Zhou P, Rothenberger NJ, Wang L, Geiger JL, Flaherty JT, Grandis JR, Bauman JE. IL6 is associated with response to dasatinib and cetuximab: Phase II clinical trial with mechanistic correlatives in cetuximab-resistant head and neck cancer. Oral Oncology. 69: 38-45. PMID 28559019 DOI: 10.1016/J.Oraloncology.2017.03.011  0.34
2017 Bauman JE, Duvvuri U, Gooding WE, Rath TJ, Gross ND, Song J, Jimeno A, Yarbrough WG, Johnson FM, Wang L, Chiosea S, Sen M, Kass J, Johnson JT, Ferris RL, et al. Randomized, placebo-controlled window trial of EGFR, Src, or combined blockade in head and neck cancer. Jci Insight. 2: e90449. PMID 28352657 DOI: 10.1172/Jci.Insight.90449  0.373
2017 Hedberg ML, Peyser N, Gooding W, Li H, Brand T, Olivas V, Bivona T, Choisea S, Wang L, Johnson J, Duvvuri U, Ferris R, Johnson D, Ha P, Bauman J, et al. Abstract 1779: Chronic NSAID use increases survival inPIK3CA-altered head and neck squamous cell carcinoma Cancer Research. 77: 1779-1779. DOI: 10.1158/1538-7445.Am2017-1779  0.36
2016 Bauman JE, Zang Y, Sen M, Li C, Wang L, Egner PA, Fahey JW, Normolle DP, Grandis JR, Kensler TW, Johnson DE. Prevention of Carcinogen-Induced Oral Cancer by Sulforaphane. Cancer Prevention Research (Philadelphia, Pa.). PMID 27339168 DOI: 10.1158/1940-6207.Capr-15-0290  0.354
2016 Peyser ND, Wang L, Zeng Y, Acquafondata M, Freilino ML, Li H, Sen M, Gooding WE, Satake M, Wang Z, Johnson DE, Grandis JR. STAT3 as a chemoprevention target in carcinogen-induced head and neck squamous cell carcinoma. Cancer Prevention Research (Philadelphia, Pa.). PMID 27267892 DOI: 10.1158/1940-6207.Capr-16-0089  0.364
2016 Hedberg ML, Goh G, Chiosea SI, Bauman JE, Freilino ML, Zeng Y, Wang L, Diergaarde BB, Gooding WE, Lui VW, Herbst RS, Lifton RP, Grandis JR. Genetic landscape of metastatic and recurrent head and neck squamous cell carcinoma. The Journal of Clinical Investigation. 126: 1606. PMID 27035818 DOI: 10.1172/Jci86862  0.352
2016 Ledgerwood LG, Kumar D, Eterovic AK, Wick J, Chen K, Zhao H, Tazi L, Manna P, Kerley S, Joshi R, Wang L, Chiosea SI, Garnett JD, Tsue TT, Chien J, et al. The degree of intratumor mutational heterogeneity varies by primary tumor sub-site. Oncotarget. PMID 27034009 DOI: 10.18632/Oncotarget.8448  0.327
2016 Peyser ND, Wang L, Acquafondata M, Freilino M, Li H, Zeng Y, Sen M, Gooding WE, Johnson DE, Grandis JR. Abstract 5243: STAT3 inhibition as chemoprevention in a chemically induced mouse model of HNSCC Cancer Research. 76: 5243-5243. DOI: 10.1158/1538-7445.Am2016-5243  0.336
2015 Van Allen EM, Lui VW, Egloff AM, Goetz EM, Li H, Johnson JT, Duvvuri U, Bauman JE, Stransky N, Zeng Y, Gilbert BR, Pendleton KP, Wang L, Chiosea S, Sougnez C, et al. Genomic Correlate of Exceptional Erlotinib Response in Head and Neck Squamous Cell Carcinoma. Jama Oncology. 1: 238-44. PMID 26181029 DOI: 10.1001/Jamaoncol.2015.34  0.345
2015 Srivastava RM, Trivedi S, Concha-Benavente F, Hyun-Bae J, Wang L, Seethala RR, Branstetter BF, Ferrone S, Ferris RL. STAT1-Induced HLA Class I Upregulation Enhances Immunogenicity and Clinical Response to Anti-EGFR mAb Cetuximab Therapy in HNC Patients. Cancer Immunology Research. PMID 25972070 DOI: 10.1158/2326-6066.Cir-15-0053  0.313
2015 Wheeler SE, Egloff AM, Wang L, James CD, Hammerman PS, Grandis JR. Challenges in EGFRvIII detection in head and neck squamous cell carcinoma. Plos One. 10: e0117781. PMID 25658924 DOI: 10.1371/Journal.Pone.0117781  0.368
2015 Srivastava R, Trivedi S, Wang L, Sheethala R, Ferrone S, Branstetter B, Ferris R. 32 STAT1 regulates HLA class I upregulation and immunogenicity after anti-EGFR mAb cetuximab therapy in head and neck cancer patients Oral Oncology. 51: e37. DOI: 10.1016/J.Oraloncology.2015.02.033  0.325
2014 Egloff AM, Lee JW, Langer CJ, Quon H, Vaezi A, Grandis JR, Seethala RR, Wang L, Shin DM, Argiris A, Yang D, Mehra R, Ridge JA, Patel UA, Burtness BA, et al. Phase II study of cetuximab in combination with cisplatin and radiation in unresectable, locally advanced head and neck squamous cell carcinoma: Eastern cooperative oncology group trial E3303. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 20: 5041-51. PMID 25107914 DOI: 10.1158/1078-0432.Ccr-14-0051  0.314
2014 Feng H, Lopez GY, Kim CK, Alvarez A, Duncan CG, Nishikawa R, Nagane M, Su AJ, Auron PE, Hedberg ML, Wang L, Raizer JJ, Kessler JA, Parsa AT, Gao WQ, et al. EGFR phosphorylation of DCBLD2 recruits TRAF6 and stimulates AKT-promoted tumorigenesis. The Journal of Clinical Investigation. 124: 3741-56. PMID 25061874 DOI: 10.1172/Jci73093  0.323
2014 Gross ND, Bauman JE, Gooding WE, Denq W, Thomas SM, Wang L, Chiosea S, Hood BL, Flint MS, Sun M, Conrads TP, Ferris RL, Johnson JT, Kim S, Argiris A, et al. Erlotinib, erlotinib-sulindac versus placebo: a randomized, double-blind, placebo-controlled window trial in operable head and neck cancer. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 20: 3289-98. PMID 24727329 DOI: 10.1158/1078-0432.Ccr-13-3360  0.321
2014 Lui VW, Peyser ND, Ng PK, Hritz J, Zeng Y, Lu Y, Li H, Wang L, Gilbert BR, General IJ, Bahar I, Ju Z, Wang Z, Pendleton KP, Xiao X, et al. Frequent mutation of receptor protein tyrosine phosphatases provides a mechanism for STAT3 hyperactivation in head and neck cancer. Proceedings of the National Academy of Sciences of the United States of America. 111: 1114-9. PMID 24395800 DOI: 10.1073/Pnas.1319551111  0.334
2014 Sen M, Paul K, Freilino ML, Li H, Li C, Johnson DE, Wang L, Eiseman J, Grandis JR. Systemic administration of a cyclic signal transducer and activator of transcription 3 (STAT3) decoy oligonucleotide inhibits tumor growth without inducing toxicological effects. Molecular Medicine (Cambridge, Mass.). 20: 46-56. PMID 24395569 DOI: 10.2119/Molmed.2013.00104  0.316
2014 Bauman JE, Duvvuri U, Gooding WE, Gross ND, Song J, Yarbrough WG, Johnson FM, Wang L, Jimeno A, Sen M, Kass JI, Johnson JT, Ferris RL, Kim S, Rath TJ, et al. Erlotinib, dasatinib, erlotinib-dasatinib versus placebo: A randomized, double-blind window study in operable head and neck squamous cell carcinoma (HNSCC). Journal of Clinical Oncology. 32: 6033-6033. DOI: 10.1200/Jco.2014.32.15_Suppl.6033  0.324
2014 Peyser ND, Wang L, Grandis JR. Abstract 5286: Promoter methylation of PTPRT provides a mechanism for STAT3 activation in HNSCC Cancer Research. 74: 5286-5286. DOI: 10.1158/1538-7445.Am2014-5286  0.312
2013 Leibowitz MS, Srivastava RM, Andrade Filho PA, Egloff AM, Wang L, Seethala RR, Ferrone S, Ferris RL. SHP2 is overexpressed and inhibits pSTAT1-mediated APM component expression, T-cell attracting chemokine secretion, and CTL recognition in head and neck cancer cells. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 19: 798-808. PMID 23363816 DOI: 10.1158/1078-0432.Ccr-12-1517  0.316
2013 Bauman JE, Gross ND, Gooding WE, Denq W, Thomas SM, Wang L, Chiosea SI, Hood BL, Flint MS, Sun M, Conrads TP, Ferris RL, Johnson JT, Kim S, Argiris A, et al. Neoadjuvant erlotinib, erlotinib-sulindac, or placebo: A randomized, double-blind biomarker modulation study in operable head and neck squamous cell carcinoma (HNSCC). Journal of Clinical Oncology. 31: 6051-6051. DOI: 10.1200/Jco.2013.31.15_Suppl.6051  0.344
2013 Mehra R, Egloff AM, Li S, Yang D, Wang L, Zhu F, Forastiere AA, Burtness B, Argiris A. Analysis of HPV and ERCC1 in recurrent or metastatic squamous cell carcinoma of the head and neck (R/M SCCHN). Journal of Clinical Oncology. 31: 6006-6006. DOI: 10.1200/Jco.2013.31.15_Suppl.6006  0.312
2012 Cassell A, Freilino ML, Lee J, Barr S, Wang L, Panahandeh MC, Thomas SM, Grandis JR. Targeting TORC1/2 enhances sensitivity to EGFR inhibitors in head and neck cancer preclinical models. Neoplasia (New York, N.Y.). 14: 1005-14. PMID 23226094 DOI: 10.1593/Neo.121212  0.35
2012 Sen M, Joyce S, Panahandeh M, Li C, Thomas SM, Maxwell J, Wang L, Gooding WE, Johnson DE, Grandis JR. Targeting Stat3 abrogates EGFR inhibitor resistance in cancer. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 18: 4986-96. PMID 22825581 DOI: 10.1158/1078-0432.Ccr-12-0792  0.342
2012 Sen M, Thomas SM, Kim S, Yeh JI, Ferris RL, Johnson JT, Duvvuri U, Lee J, Sahu N, Joyce S, Freilino ML, Shi H, Li C, Ly D, Rapireddy S, ... ... Wang L, et al. First-in-human trial of a STAT3 decoy oligonucleotide in head and neck tumors: implications for cancer therapy. Cancer Discovery. 2: 694-705. PMID 22719020 DOI: 10.1158/2159-8290.Cd-12-0191  0.332
2012 Wheeler S, Siwak DR, Chai R, LaValle C, Seethala RR, Wang L, Cieply K, Sherer C, Joy C, Mills GB, Argiris A, Siegfried JM, Grandis JR, Egloff AM. Tumor epidermal growth factor receptor and EGFR PY1068 are independent prognostic indicators for head and neck squamous cell carcinoma. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 18: 2278-89. PMID 22351687 DOI: 10.1158/1078-0432.Ccr-11-1593  0.327
2011 Argiris A, Lee SC, Feinstein T, Thomas S, Branstetter BF, Seethala R, Wang L, Gooding W, Grandis JR, Ferris RL. Serum biomarkers as potential predictors of antitumor activity of cetuximab-containing therapy for locally advanced head and neck cancer. Oral Oncology. 47: 961-6. PMID 21889392 DOI: 10.1016/J.Oraloncology.2011.07.034  0.342
2011 Stransky N, Egloff AM, Tward AD, Kostic AD, Cibulskis K, Sivachenko A, Kryukov GV, Lawrence MS, Sougnez C, McKenna A, Shefler E, Ramos AH, Stojanov P, Carter SL, Voet D, ... ... Wang L, et al. The mutational landscape of head and neck squamous cell carcinoma. Science (New York, N.Y.). 333: 1157-60. PMID 21798893 DOI: 10.1126/Science.1208130  0.322
2011 Vaezi A, Wang X, Buch S, Gooding W, Wang L, Seethala RR, Weaver DT, D'Andrea AD, Argiris A, Romkes M, Niedernhofer LJ, Grandis JR. XPF expression correlates with clinical outcome in squamous cell carcinoma of the head and neck. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 17: 5513-22. PMID 21737503 DOI: 10.1158/1078-0432.Ccr-11-0086  0.301
2010 Argiris A, Heron DE, Smith RP, Kim S, Gibson MK, Lai SY, Branstetter BF, Posluszny DM, Wang L, Seethala RR, Dacic S, Gooding W, Grandis JR, Johnson JT, Ferris RL. Induction docetaxel, cisplatin, and cetuximab followed by concurrent radiotherapy, cisplatin, and cetuximab and maintenance cetuximab in patients with locally advanced head and neck cancer. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 28: 5294-300. PMID 21079141 DOI: 10.1200/Jco.2010.30.6423  0.314
Show low-probability matches.